News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Week in Review: Hutchison Medipharma and AstraZeneca PLC (AZN) Partner on Cancer Drug


12/28/2011 9:16:48 AM

December 24, 2011 -- Hutchison MediPharma and AstraZeneca formed a partnership to develop a novel cancer molecule; Hua Medicine in-licensed global rights to diabetes treatment program; Shunfeng Pharma is auctioning itself off to the highest bidder, which is expected to be Sanjiu Medical; Beijing Double-Crane Pharma will pay $17.4 million to buy Henan Shuanghe Huali Pharma; Beijing SL Pharma and Lin Chia announced a US-based JV; ForteBio, a maker of biotech drug development tools, was acquired by Pall Corporation; BioTime optioned antibody-producing cell lines from USCN Life Science China; Frontage Labs opened a renovated clinical-stage facility for cancer in Jilin University Hospital; Jiangsu Hengrui Medicine was granted FDA approval for a chemotherapy drug; and DSM Sinochem announced plans to build a manufacturing facility in Shandong province. More details….

Stock Symbols: (NYSE: AZN) (SIX: ROG) (SHE: 000999) (SHA: 600062) (SHE: 002038) (NYSE: PLL) (AMEX: BTX) (SHA: 600276)


Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES